Emerging protein kinase inhibitors for non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q38172608

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging protein kinase inhibitors for non-small cell lung cancer.

@en

type

Item

label

Emerging protein kinase inhibitors for non-small cell lung cancer.

@en

prefLabel

Emerging protein kinase inhibitors for non-small cell lung cancer.

@en

P1476

Emerging protein kinase inhibitors for non-small cell lung cancer.

@en

P2093

Deepa Subramaniam

http://www.w3.org/2001/XMLSchema#string

Feras J Abdul-Khalek

http://www.w3.org/2001/XMLSchema#string

George C Cyriac

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

ROS1 rearrangements define a unique molecular class of lung cancers.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

P304

51-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2014.873403

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

Stephen V Liu

P577

2013-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24354593

http://www.w3.org/2001/XMLSchema#string